Cargando…

Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition

Chemotherapy-induced side effects restrain anti-tumor efficiency, with hyperlipidemia being the most common accompanying disease to cause treatment failure. In this work, a chimeric peptide-engineered nanomedicine (designated as PRS) was fabricated for the synergistic suppression of tumor growth and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Hua, Zheng, Rongrong, Wu, Ningxia, Hu, Jiaman, Wang, Ruixin, Chi, Jianing, Zhang, Wei, Zhao, Linping, Cheng, Hong, Chen, Ali, Li, Shiying, Xu, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610039/ https://www.ncbi.nlm.nih.gov/pubmed/37896137 http://dx.doi.org/10.3390/pharmaceutics15102377

Ejemplares similares

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Circulating levels of DDIT4 and mTOR, and contributions of BMI, inflammation and insulin sensitivity in hyperlipidemia
por: Pan, Xinyan, et al.
Publicado: (2022)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
por: Spormann, Luise, et al.
Publicado: (2020)

The prognostic nutritional index predicts all-cause mortality in critically ill patients with acute myocardial infarction
por: Huang, Yuekang, et al.
Publicado: (2023)

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma
por: Kling, Matthew J., et al.
Publicado: (2021)

Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors
por: Jacome Sanz, Dafne, et al.
Publicado: (2021)

A Critical Role of PCSK9 in Mediating IL-17-Producing T Cell Responses in Hyperlipidemia
por: Kim, Young Uk, et al.
Publicado: (2019)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
por: Waldmann, Elisa, et al.
Publicado: (2022)

Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
por: Xu, Chenyue, et al.
Publicado: (2022)

Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis
por: Wu, Yue, et al.
Publicado: (2019)

Peptide-MHC-Based Nanomedicines for the Treatment of Autoimmunity: Engineering, Mechanisms, and Diseases
por: Serra, Pau, et al.
Publicado: (2021)

Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia
por: Huang, Congwu, et al.
Publicado: (2014)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
por: Grabinski, Nicole, et al.
Publicado: (2012)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth
por: Soliman, Ghada A, et al.
Publicado: (2020)

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
por: Kim, Hyera, et al.
Publicado: (2020)

Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells
por: Reita, Damien, et al.
Publicado: (2019)

Prognostic impact of in-hospital hemoglobin decline in non-overt bleeding ICU patients with acute myocardial infarction
por: Li, Pengfei, et al.
Publicado: (2023)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(−/−) mice may be associated with increased PCSK9 expression
por: Zhao, Xue-Shan, et al.
Publicado: (2017)

Ginsenoside Rg1 Alleviates Podocyte Injury Induced by Hyperlipidemia via Targeting the mTOR/NF-κB/NLRP3 Axis
por: Wang, Tao, et al.
Publicado: (2020)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

The Efficacy and Safety of the mTOR Signaling Pathway Activator, MHY1485, for in vitro Activation of Human Ovarian Tissue
por: Wu, Shuang, et al.
Publicado: (2021)

Promotion of Ovarian Follicle Growth following mTOR Activation: Synergistic Effects of AKT Stimulators
por: Cheng, Yuan, et al.
Publicado: (2015)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma
por: Sun, Kaiyan, et al.
Publicado: (2023)

Zein-Based Nanomedicines for Synergistic Chemodynamic/Photodynamic Therapy
por: Li, Xiang, et al.
Publicado: (2022)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Transient inhibition of mTOR in human pluripotent stem cells enables robust formation of mouse-human chimeric embryos
por: Hu, Zhixing, et al.
Publicado: (2020)

Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque
por: Basiak, Marcin, et al.
Publicado: (2022)

Discovery of a potent FKBP38 agonist that ameliorates HFD-induced hyperlipidemia via mTOR/P70S6K/SREBPs pathway
por: Xiao, Ping-Ting, et al.
Publicado: (2021)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma
por: Temblador, Arturo, et al.
Publicado: (2022)

Recent trends in nanomedicine and tissue engineering
por: Thomas, Jince, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ougp8nkdsh1c4sis6bu1dk9mqn